Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Number experiencing hypotensive or other adverse effects · People undergoing managed opioid withdrawal

Alpha2‐adrenergic agonist may leads to higher number experiencing hypotensive or other adverse effects compared with methadone (low certainty).

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
RR 1.92 [1.19, 3.1]
6 studies · 464 participants
Low

Number experiencing adverse effects · Adults or adolescents with opioid dependence

It is very uncertain whether buprenorphine changes number experiencing adverse effects compared with alpha2‐adrenergic agonists (very low certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
RR 0.93 [0.7, 1.26]
3 studies · 493 participants
Very low